Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy

Abstract Background Hepatitis B virus-related acute-on-chronic liver failure (HBV–ACLF) is frequently accompanied by short-term morbidity and mortality. However, there have been no studies on the associations between baseline clinicopathologic characteristics at hospital admission and clinical progn...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaofang Wang, Ziyue Yang, Zhangya Pu, Yixiang Zheng, Haiou Chen, Yan Huang, Xuegong Fan, Panpan Yi
Format: Article
Language:English
Published: BMC 2024-11-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-024-02141-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846158689423065088
author Xiaofang Wang
Ziyue Yang
Zhangya Pu
Yixiang Zheng
Haiou Chen
Yan Huang
Xuegong Fan
Panpan Yi
author_facet Xiaofang Wang
Ziyue Yang
Zhangya Pu
Yixiang Zheng
Haiou Chen
Yan Huang
Xuegong Fan
Panpan Yi
author_sort Xiaofang Wang
collection DOAJ
description Abstract Background Hepatitis B virus-related acute-on-chronic liver failure (HBV–ACLF) is frequently accompanied by short-term morbidity and mortality. However, there have been no studies on the associations between baseline clinicopathologic characteristics at hospital admission and clinical prognosis after receiving artificial liver therapy. Therefore, the current study aimed to develop a prognostic nomogram for predicting the outcomes of patients with HBV–ACLF following artificial liver support. Methods A retrospective study of 110 consecutive patients who were diagnosed with HBV–ACLF between January 2018 and August 2022 was conducted. First, univariate and multivariate logistic regression analyses were performed to determine the independent prognostic factors significantly associated with patient outcomes. Moreover, a predictive nomogram model underlying the prognostic factors was established and further evaluated. The area under the curve (AUC) was used to gauge the predictive accuracy. The calibration curve and decision curve analysis (DCA) were employed to assess the discriminability and clinical effectiveness, respectively. Results In patients with HBV–ACLF, multivariate logistic analysis revealed that age ≥ 40 years (OR 6.76, p = 0.025), middle-stage liver failure (OR 49.96, p < 0.001), end-stage liver failure (OR 19.27, p = 0.002), hepatic encephalopathy (OR 7.06, p = 0.032), upper gastrointestinal hemorrhage (OR 47.24, p = 0.047), and artificial liver therapy consisting of plasma exchange (PE) + plasma exchange double plasma molecular adsorption system (DPMAS) (OR 0.26, p = 0.04) were identified as prognostic factors. Then, we established and evaluated a predictive nomogram with an AUC of 0.885, which showed better predictive accuracy than the model for end-stage liver disease (MELD) score (AUC of 0.634) and the Child–Pugh score (AUC of 0.611). Moreover, the calibration curve showed good agreement between the ideal and bias-corrected curves. Decision curve analysis confirmed the better clinical utility of this approach. Conclusions We developed and evaluated a unique nomogram that was more accurate than conventional prognostic models for predicting the clinical prognosis of HBV–ACLF patients receiving artificial liver therapy. As a result, the nomogram may be a helpful tool in clinical decision-making to predict the outcomes of patients with HBV–ACLF.
format Article
id doaj-art-b57c2db6a24247658582abd8c7929fa1
institution Kabale University
issn 2047-783X
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj-art-b57c2db6a24247658582abd8c7929fa12024-11-24T12:16:18ZengBMCEuropean Journal of Medical Research2047-783X2024-11-0129111010.1186/s40001-024-02141-7Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapyXiaofang Wang0Ziyue Yang1Zhangya Pu2Yixiang Zheng3Haiou Chen4Yan Huang5Xuegong Fan6Panpan Yi7Department of Infectious Disease, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University)Department of Blood Transfusion, Xiangya Hospital, Central South UniversityDepartment of Infectious Disease, The First Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South UniversityDepartment of Infectious Disease, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University)Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South UniversityDepartment of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South UniversityDepartment of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital, Central South UniversityAbstract Background Hepatitis B virus-related acute-on-chronic liver failure (HBV–ACLF) is frequently accompanied by short-term morbidity and mortality. However, there have been no studies on the associations between baseline clinicopathologic characteristics at hospital admission and clinical prognosis after receiving artificial liver therapy. Therefore, the current study aimed to develop a prognostic nomogram for predicting the outcomes of patients with HBV–ACLF following artificial liver support. Methods A retrospective study of 110 consecutive patients who were diagnosed with HBV–ACLF between January 2018 and August 2022 was conducted. First, univariate and multivariate logistic regression analyses were performed to determine the independent prognostic factors significantly associated with patient outcomes. Moreover, a predictive nomogram model underlying the prognostic factors was established and further evaluated. The area under the curve (AUC) was used to gauge the predictive accuracy. The calibration curve and decision curve analysis (DCA) were employed to assess the discriminability and clinical effectiveness, respectively. Results In patients with HBV–ACLF, multivariate logistic analysis revealed that age ≥ 40 years (OR 6.76, p = 0.025), middle-stage liver failure (OR 49.96, p < 0.001), end-stage liver failure (OR 19.27, p = 0.002), hepatic encephalopathy (OR 7.06, p = 0.032), upper gastrointestinal hemorrhage (OR 47.24, p = 0.047), and artificial liver therapy consisting of plasma exchange (PE) + plasma exchange double plasma molecular adsorption system (DPMAS) (OR 0.26, p = 0.04) were identified as prognostic factors. Then, we established and evaluated a predictive nomogram with an AUC of 0.885, which showed better predictive accuracy than the model for end-stage liver disease (MELD) score (AUC of 0.634) and the Child–Pugh score (AUC of 0.611). Moreover, the calibration curve showed good agreement between the ideal and bias-corrected curves. Decision curve analysis confirmed the better clinical utility of this approach. Conclusions We developed and evaluated a unique nomogram that was more accurate than conventional prognostic models for predicting the clinical prognosis of HBV–ACLF patients receiving artificial liver therapy. As a result, the nomogram may be a helpful tool in clinical decision-making to predict the outcomes of patients with HBV–ACLF.https://doi.org/10.1186/s40001-024-02141-7Hepatitis B virusAcute-on-chronic liver failureDouble plasma molecular adsorption systemHalf-dose plasma exchangeArtificial liver therapyNomogram
spellingShingle Xiaofang Wang
Ziyue Yang
Zhangya Pu
Yixiang Zheng
Haiou Chen
Yan Huang
Xuegong Fan
Panpan Yi
Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
European Journal of Medical Research
Hepatitis B virus
Acute-on-chronic liver failure
Double plasma molecular adsorption system
Half-dose plasma exchange
Artificial liver therapy
Nomogram
title Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
title_full Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
title_fullStr Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
title_full_unstemmed Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
title_short Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
title_sort development and validation of a novel prognostic nomogram for hepatitis b virus related acute on chronic liver failure patients receiving artificial liver therapy
topic Hepatitis B virus
Acute-on-chronic liver failure
Double plasma molecular adsorption system
Half-dose plasma exchange
Artificial liver therapy
Nomogram
url https://doi.org/10.1186/s40001-024-02141-7
work_keys_str_mv AT xiaofangwang developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT ziyueyang developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT zhangyapu developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT yixiangzheng developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT haiouchen developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT yanhuang developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT xuegongfan developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy
AT panpanyi developmentandvalidationofanovelprognosticnomogramforhepatitisbvirusrelatedacuteonchronicliverfailurepatientsreceivingartificiallivertherapy